Price alert —
Sign in to get a one-time email the moment QGEN crosses your price. Free accounts included.
Sign in / create a free accountQiagen N.V. is a healthcare company listed in the US.
QGEN last traded at $41.15, down 0.9% on the day; that's in the middle part of its 52-week range ($32.53–$57.82). Right now it's trading above its recent average — momentum is positive, though some of the move may already be in the price.
Earnings reports are the biggest scheduled catalysts to keep an eye on, and after a strong run, watch whether the price can hold its gains on quieter days.
A plain-English snapshot built from the data on this page — not investment advice. Always do your own research.
On the latest daily bar, momentum sits mid-range (RSI 61), the trend is strong (ADX 30), and trading is light at 0.7× normal volume. On the business side, revenue is growing 2% year over year and the business keeps about 11 cents of every sales dollar as free cash.
Latest-bar indicator readings behind the grade — display-only, they don't move the letter.
Company fundamentals for context — display-only, they don't move the grade.
Our cash-flow model pegs fair value near $11.89 (fair range $12–$37); today's price sits 249% above that estimate. The model's verdict is “Overvalued” and accounting quality screens as Weak. Model estimates only — do your own due diligence.
- ✓ Quick ratio 2.05 (antifragile)
- ✓ Current ratio 3.90 (antifragile)
- ✓ Debt/equity 0.66 (antifragile)
- ✓ Positive retained earnings
- ⚠ Debt exceeds cash
- ⚠ Receivables growing faster than revenue
Price implies ~19% growth (vs trailing rev yoy). Model estimate — do your own due diligence.
QGEN is a $8.5 billion company, priced at 21× last year's earnings.